NAMHC Clinical High Risk for Psychosis Workgroup Charge
| Roster |
The Clinical High Risk (CHR) for Psychosis Workgroup brings together key public and private stakeholders in early intervention for schizophrenia, to advise the National Advisory Mental Health Council on initiatives to qualify biomarkers and clinical endpoints that reliably predict psychosis and non-psychosis outcomes. The goal of the initiatives is to provide tools to help develop successful treatments for CHR for psychosis. The workgroup met to discuss the outcomes of two Requests for Applications (RFAs) on this topic. The Chair of the workgroup presented a summary of the workgroup’s feedback on the two RFAs at the special meeting of Council in August 2020.